FDA Approves Moderna's 1st mRNA Flu Shot: Timeline

Health The FDA recently approved Moderna's mRNA-based influenza vaccine, mRESVIA, marking the first time an mRNA technology has been cleared for a flu shot. This appr… Swipe to explore › AiTimeline Home

Early Research Demonstrates mRNA's Potential as a Therapeutic Agent

MRNA PIONEERING RESEARCH Researchers at the University of Wisconsin-Madison and other institutions published seminal work showing that mRNA could be delivered into cells to produce proteins. Thi… AiTimeline Home

Katalin Karikó and Drew Weissman Discover Pseudouridine's Role in mRNA

PSEUDOURIDINE DISCOVERY Katalin Karikó and Drew Weissman at the University of Pennsylvania published their discovery that incorporating modified nucleosides, particularly pseudouridine, into mR… AiTimeline Home

Moderna Therapeutics is Founded to Commercialize mRNA Technology

MODERNA FOUNDED Moderna Therapeutics was founded with the ambitious goal of developing drugs based on messenger RNA. The company aimed to leverage the nascent mRNA technology to create… AiTimeline Home

Moderna Initiates its Influenza Vaccine Development Program

FLU VACCINE PROGRAM LAUNCHED Building on its growing expertise in mRNA technology, Moderna officially launched its influenza vaccine program. This strategic move aimed to apply the rapid development… AiTimeline Home

FDA Grants Emergency Use Authorization for Moderna COVID-19 Vaccine

COVID-19 VACCINE EUA The U.S. FDA granted Emergency Use Authorization (EUA) for Moderna's COVID-19 vaccine (mRNA-1273), a pivotal moment for mRNA technology. This rapid approval during a glo… AiTimeline Home

Moderna Presents Positive Phase 1 Data for mRNA Flu Vaccine Candidate

FLU VACCINE PHASE 1 DATA Moderna announced positive interim Phase 1 data for its quadrivalent mRNA influenza vaccine candidate (mRNA-1010), demonstrating robust immune responses against all four… AiTimeline Home

Moderna Initiates Pivotal Phase 3 Trial for mRNA Flu Vaccine

PHASE 3 TRIAL INITIATION Moderna initiated a global pivotal Phase 3 clinical trial for its mRNA influenza vaccine candidate, mRNA-1010 (later named mRESVIA). This large-scale trial aimed to asse… AiTimeline Home

Moderna Announces Positive Efficacy Data from Phase 3 Trial

PHASE 3 POSITIVE DATA Moderna announced positive results from its Phase 3 trial for mRESVIA (mRNA-1010), demonstrating superior efficacy against influenza A and comparable efficacy against in… AiTimeline Home

FDA Approves Moderna's mRESVIA, the First mRNA Flu Shot

FDA APPROVAL The U.S. Food and Drug Administration (FDA) officially approved mRESVIA (mRNA-1010), Moderna's mRNA-based influenza vaccine, for the prevention of influenza disease in a… AiTimeline Home

Want the full timeline?

Read the complete story, FAQs and key facts. AiTimeline Home